Evidence map›Paper›PMID 40066510›Full record

ArticleAdvanced healthcare materials2025

An In Situ Curing, Shear-Responsive Biomaterial Designed for Durable Embolization of Microvasculature.

Quynh P Pham, Jeffrey V Groom, Chander Sadasivan, David J Fiorella, David C Madoff, Lee-Jae Guo, Michael Fornaciari, Courtney Guertin, Craig Wiltsey, Lee Core and 7 more

Registry-linked trialAbstract read
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07541404 (Pivotal Study of the Treatment of Symptomatic Subacute and Chronic Subdural Hematoma Via Middle Meningeal Artery Embolization With the NeoCastTM Embolic System), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07541404 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Pivotal Study of the Treatment of Symptomatic Subacute and Chronic Subdural Hematoma Via Middle Meningeal Artery Embolization With the NeoCastTM Embolic System (RADIANT)

TypeinterventionalSponsorArsenal Medical, Inc.Ran2026 to 2028Enrolled360ConditionsSubdural HematomaArmsNeoCast Embolic System, Onyx LES, an FDA-Approved Commercial Liquid Embolic
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Quynh P PhamArsenal Medical, Inc, 100 Beaver Street, Suite 302, Waltham, MA, 02453, USA.ORCID 0009-0001-0263-0634
Jeffrey V GroomArsenal Medical, Inc, 100 Beaver Street, Suite 302, Waltham, MA, 02453, USA.
Chander SadasivanDepartment of Neurological Surgery, Stony Brook Medicine, 101 Nicolls Road, Stony Brook, NY, 11794, USA.ORCID 0000-0002-6305-9785
David J FiorellaDepartment of Neurological Surgery, Stony Brook Medicine, 101 Nicolls Road, Stony Brook, NY, 11794, USA.ORCID 0000-0002-2677-8780
David C MadoffDepartment of Radiology and Biomedical Imaging, Yale University, 333 Cedar St., New Haven, CT, 06510, USA.ORCID 0000-0003-3461-437X
Lee-Jae GuoCBSET, Inc, 500 Shire Way, Lexington, MA, 02421, USA.
Michael FornaciariArsenal Medical, Inc, 100 Beaver Street, Suite 302, Waltham, MA, 02453, USA.
Courtney GuertinArsenal Medical, Inc, 100 Beaver Street, Suite 302, Waltham, MA, 02453, USA.
Craig WiltseyArsenal Medical, Inc, 100 Beaver Street, Suite 302, Waltham, MA, 02453, USA.
Lee CoreArsenal Medical, Inc, 100 Beaver Street, Suite 302, Waltham, MA, 02453, USA.
Jonathan MerloArsenal Medical, Inc, 100 Beaver Street, Suite 302, Waltham, MA, 02453, USA.
William WustenbergMycroft Medical LLC, 20828 Ahern Blvd., Farmington, MN, 55024, USA.
Renu VirmaniCVPath Institute Inc, 19 Firstfield Rd., Gaithersburg, MD, 20878, USA.
Adam S ArthurDepartment of Neurosurgery, University of Tennessee Health Science Center, 847 Monroe Ave, Memphis, TN, 38163, USA.ORCID 0000-0002-1536-1613
Robert S LangerDepartment of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA.ORCID 0000-0003-4255-0492
George M WhitesidesDepartment of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, MA, 02138, USA.ORCID 0000-0003-1184-6573
Upma SharmaArsenal Medical, Inc, 100 Beaver Street, Suite 302, Waltham, MA, 02453, USA.ORCID 0009-0009-9922-1551

Funding

Flow Responsive Embolic Agent for the Complete Devascularization of MeningiomasR44CA257802 · NCI · ARSENAL MEDICAL, INC. · PI PHAM, QUYNH P · 2021 to 2022
$1.9M
Ideal Embolic for Portal Vein EmbolizationR43HL154865 · NHLBI · ARSENAL MEDICAL, INC. · PI PHAM, QUYNH P · 2020 to 2020
$367k
NCI NIH HHS R44 CA257802NCI NIH HHS R44CA257802NHLBI NIH HHS R43 HL154865NHLBI NIH HHS R43HL154865
6 · The paper itself

Abstract

Endovascular embolization is a minimally-invasive technique whereby blood vessels supplying pathological structures are selectively occluded with various embolic agents. In many scenarios, it is desirable for the embolic to distally penetrate to the level of the microvasculature, which maximizes devascularization. Existing agents exhibit inconsistent distal penetration and have other limitations including tendency for proximal reflux, patient pain during infusion, lack of fluoroscopic radiopacity, potential for catheter adhesion, susceptibility to recanalization, and other usability challenges. NeoCast is an in situ curing, solvent-free, non-adhesive biomaterial composed of polydimethylsiloxane, bismuth trioxide, and fumed silica that possesses shear-responsive properties enabling manual injectability through commercially-available microcatheters with large and small diameter lumens. Here, embolization performance with and without flow arrest, in both arterial and venous preclinical anatomies is reported. NeoCast reproducibly achieves a rate of distal penetration with microvascular occlusion that is superior to existing agents, exhibits excellent fluoroscopic visibility, and provides durable occlusion. There is mild inflammation when NeoCast is infused into blood vessels and absence of neurotoxicity when implanted directly into brain tissue. The engineered NeoCast material is poised to become a next-generation, liquid embolic agent for applications in which distal microvascular occlusion is desired.

Indexed as

Biocompatible MaterialsEmbolization, TherapeuticMicrovesselsAnimalsBismuthDimethylpolysiloxanesHumansMiceSilicon DioxidebaysilonBiocompatible MaterialsBismuthDimethylpolysiloxanesSilicon Dioxidebiomaterialembolicmicrovascularocclusionshear‐responsive

Identifiers

PMID40066510
PMCPMC12147989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.